Outset Medical (NASDAQ:OM – Get Free Report) and Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.
Volatility and Risk
Outset Medical has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500. Comparatively, Guided Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.
Institutional & Insider Ownership
9.7% of Guided Therapeutics shares are owned by institutional investors. 3.5% of Outset Medical shares are owned by insiders. Comparatively, 66.8% of Guided Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Outset Medical | -136.72% | -143.52% | -48.89% |
Guided Therapeutics | N/A | N/A | -138.23% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Outset Medical and Guided Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Outset Medical | 1 | 2 | 4 | 0 | 2.43 |
Guided Therapeutics | 0 | 0 | 0 | 0 | N/A |
Outset Medical presently has a consensus price target of $4.64, suggesting a potential upside of 539.42%. Given Outset Medical’s higher possible upside, analysts plainly believe Outset Medical is more favorable than Guided Therapeutics.
Valuation & Earnings
This table compares Outset Medical and Guided Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Outset Medical | $130.38 million | 0.28 | -$172.80 million | ($3.38) | -0.20 |
Guided Therapeutics | $100,000.00 | 53.72 | -$3.49 million | N/A | N/A |
Guided Therapeutics has lower revenue, but higher earnings than Outset Medical.
Summary
Guided Therapeutics beats Outset Medical on 6 of the 11 factors compared between the two stocks.
About Outset Medical
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
About Guided Therapeutics
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.